EDAP HIFU and Lithotripsy Devices Showcased at 31st Annual European Association of Urology Congress

LYON, France, March 17, 2016 (GLOBE NEWSWIRE) — EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its HIFU and lithotripsy devices were highlighted at the European Association of Urology (EAU) 2016 Annual Congress held in Munich, Germany, on March 11-15, 2016.

The EAU congress is one of the preeminent international events dedicated to the urology community. EDAP presented posters and videos showing clinical results of trials using its Ablatherm® and Focal One® HIFU devices, while at the EDAP booth, the Company featured continuous demonstrations of its Focal One® Robotic HIFU and its lithotripsy devices. The booth also hosted numerous discussions among current and prospective users of EDAP’s technology.

Additionally, a forum dedicated to technological and clinical advancements using EDAP’s HIFU technology gathered experienced Ablatherm and Focal One practitioners and key opinion leaders, including:

  • Dr. S. Thueroff, from Harlaching Hospital, Munich, Germany,
  • Pr. P. Rischman from Rangueil University Hospital, Toulouse, France,
  • Pr. R. van Velthoven, from Institut Bordet Oncology Center, Brussels, Belgium, and
  • Pr. S. Crouzet, from Edouard Herriot University Hospital, Lyon, France.

Marc Oczachowski, EDAP’s Chief Executive Officer, commented, “Once again, the EAU congress was highly attended, and our presence resulted in numerous promising sales leads for our unique and innovative range of non-invasive products and technologies.  The growing global acceptance of the focal HIFU approach to addressing prostate pathologies was clear at the congress, which bodes extremely well for EDAP. With our HIFU technology now approved for ablation of prostatic tissue in most countries in the world, we are confident that EDAP offers the right approach to treat prostate diseases, at the right time.”

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters’ range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

Forward-Looking Statements
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company’s filings with the Securities and Exchange Commission and in particular, in the sections “Cautionary Statement on Forward-Looking Information” and “Risk Factors” in the Company’s Annual Report on Form 20-F.


CONTACT: Contact: 
Blandine Confort
Investor Relations / Legal Affairs
+33 4 72 15 31 72

Lee Roth 
The Ruth Group